Proposed flat payment rates for 2027 by CMS intensify margin pressures on Medicare Advantage insurers like Clover Health, raising investor concerns about cost management and growth prospects in a tightening regulatory landscape.
Cardinal Health (CAH) stock has drawn renewed investor interest following robust financial results, with revenue topping $234 billion and net income near $1.6 billion. The healthcare distributor's shares have rallied over 66% in the past year, though its premium valuation compared to peers is sparking debate among analysts.
Facing uneven long-term performance, UPS announces a major strategic overhaul involving significant job reductions, facility closures, and a deliberate move away from low-margin Amazon volume. The company is betting big on healthcare logistics through acquisitions to bolster its global cold chain network.
Lumen Technologies pivots decisively toward the enterprise sector, achieving a pioneering AI management certification while divesting its remaining consumer fiber assets to AT&T, signaling a strategic consolidation around business and government services.
After a punishing year for many restaurant stocks, a seismic shift is underway. As inflation-weary diners become more selective, value and experience are trumping category labels, driving a surprising resurgence in casual dining while challenging the fast-casual model.
Bank of America has revised its price target for consumer goods giant Kimberly-Clark downward, citing sector-wide valuation pressures, even as the company reports resilient earnings and advances its transformation into a broader health and wellness player.
Cocoa futures have plunged to multi-year lows, pressured by a global surplus and weakening demand as high chocolate prices curb consumption. Analysts point to favorable harvests in West Africa and falling processing volumes as key factors extending the market's month-long decline.
Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.
A growing financial strategy known as 'soft switching'—opening new bank accounts without closing old ones—is gaining traction. Experts say it can unlock higher yields, better features, and greater flexibility, but requires careful management to avoid pitfalls.
A months-long advocacy campaign criticizing Hannaford's pricing and animal welfare policies has gained little traction among Maine shoppers, many of whom remain loyal to the dominant grocer despite concerns over affordability.
The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.
The Ermenegildo Zegna Group reported a 1.1% organic revenue increase to €1.91 billion for 2025, powered by robust DTC performance. While annual sales dipped slightly on a reported basis, a strong fourth-quarter acceleration signals the payoff of its strategic channel shift.
A deep dive into the conflicting signals from Church & Dwight's stock valuation. While a discounted cash flow model suggests a significant discount, its premium P/E ratio tells a different story, leaving investors to weigh pricing power against market expectations.
Despite a 5% share price gain over the last quarter, a deep dive into Fevara plc's (LON:FVA) fundamentals reveals concerning trends. With a declining net income and a high dividend payout strategy stifling reinvestment, analysts question the sustainability of its current valuation.
As Mondelez International prepares to report its quarterly results, investors are watching for signs of sustained growth and margin recovery in a competitive packaged foods landscape.
As J&J Snack Foods prepares to release its quarterly results, investors are weighing stable analyst expectations against a backdrop of mixed performance in the shelf-stable food sector.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
A strategic report warns that recent tariff hikes could significantly increase clothing costs for American shoppers unless brands rapidly diversify production to a network of partner nations.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
An unexpected jump in the Producer Price Index for December underscores the stubborn nature of inflation, with rising wholesale costs threatening to ripple through the economy and sustain higher prices for households.
